Biologicals
BSI Secures New Funding for Quillibrium Biofungicide and QS-21 Vaccine Adjuvant Development
Investment will be used to scale up production of the vaccine adjuvant and fulfill the supply agreements with Croda and other Big Pharma companies.
Agtech
Sustainable Podcast: Rovensa Next’s Brazilian Researchers Use Grower Collaboration as a Catalyst for Innovation
Dr. Rafael Leiria and Dr. Johana Rincones Pérez share...
Biologicals
Trade Summit: Mending the Great Biological/Chemical Divide
A trio of speakers at the AgriBusiness Global Trade...
Americas
ADAMA Receives Registration for ACTAVAN Biofungicide in Peru
ACTAVAN is ADAMA's first global biofungicide developed in collaboration...
Biologicals
Bio-Gene Forms Agreement with STK to Develop Qcide Botanical-Based Technology
Bio-Gene grants STK a worldwide, nonexclusive license to develop...
Biologicals
New Opportunities for the Burgeoning Biostimulant Market
Despite the explosion of biostimulants, there is still huge...